NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Waaree Energies Subsidiary Acquires 100% Stake in Waaree Semicon for INR 1 Lakh
Waaree Energies' subsidiary, Waaree Power Private Limited, has completed the acquisition of a 100% equity stake in Waaree Semicon Private Limited. The transaction was finalized for a nominal cash consideration of INR 1 lakh. Consequently, Waaree Semicon has become a step-down subsidiary of the company as of May 15, 2026. This acquisition marks a strategic move for the group into the semiconductor domain, although the current financial outlay is minimal.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake in Waaree Semicon Private Limited.Total cash consideration for the deal is INR 1 lakh.Waaree Semicon is now a step-down subsidiary of Waaree Energies.The acquisition was completed on May 15, 2026, following an April 29 disclosure.
👀 கவனிக்க வேண்டியவை
Investors should track the company's roadmap for the semiconductor business, as this small-ticket acquisition likely serves as a vehicle for future expansion. The immediate financial impact is negligible, but the strategic intent is noteworthy.
Waaree Energies to Seek Shareholder Approval for ₹10,000 Crore Fundraise via QIP
Waaree Energies has issued a postal ballot notice to seek shareholder approval for a massive capital raise of up to ₹10,000 crores through a Qualified Institutions Placement (QIP). The company is also seeking the formal appointment of Mr. Jignesh Devchandbhai Rathod as Whole-Time Director and CEO for a five-year term effective March 21, 2026. The e-voting period for these resolutions is set from May 15, 2026, to June 13, 2026. This significant capital infusion indicates the company's intent for aggressive expansion or strengthening its balance sheet in the competitive solar energy sector.
முக்கிய அம்சங்கள்
Proposed capital raise of up to ₹10,000 crores through Qualified Institutions Placement (QIP)Appointment of Jignesh Devchandbhai Rathod as Whole-Time Director and CEO for a 5-year tenureE-voting period for shareholders scheduled from May 15, 2026, to June 13, 2026The fundraise may involve Equity Shares or other eligible convertible securities in one or more tranches
👀 கவனிக்க வேண்டியவை
Investors should watch for the specific utilization plan of the ₹10,000 crore fundraise, as it signals major growth but will result in equity dilution. Monitor the new CEO's strategic roadmap for the company's next phase of expansion.
Saregama Q4 Net Profit Rises 24% to ₹74 Cr; FY26 Music Segment Revenue Grows 9%
Saregama reported a strong Q4 FY26 with consolidated net profit rising 23.8% YoY to ₹74.14 crore. While full-year FY26 revenue declined to ₹984.62 crore from ₹1,171.36 crore in FY25, this was primarily due to a sharp contraction in the volatile Events segment. The core Music segment showed resilience, with annual revenue growing 9.4% to ₹683.52 crore. Overall annual profitability remained stable with a net profit of ₹206.22 crore and a slight improvement in EPS to ₹10.73.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated net profit increased to ₹74.14 crore vs ₹59.86 crore in Q4 FY25.Full-year FY26 revenue from operations stood at ₹984.62 crore, down from ₹1,171.36 crore in FY25.Music segment annual revenue grew to ₹683.52 crore, contributing the bulk of segment results at ₹364.09 crore.Events segment revenue saw a significant drop to ₹61.83 crore in FY26 from ₹285.23 crore in the previous year.The Board approved an updated Insider Trading Prohibition Code and authorized KMPs for materiality disclosures.
👀 கவனிக்க வேண்டியவை
Investors should look past the headline revenue decline caused by the low-margin Events business and focus on the steady growth of the high-margin Music IP segment. Monitor the company's ability to scale Artist Management and Video segments as secondary growth drivers.
Saregama Q4 Net Profit Rises 25% YoY to ₹75.4 Cr; Music & Artist Management Lead Growth
Saregama reported a strong Q4 FY26 performance with consolidated revenue growing 19.4% YoY to ₹287.4 crore and net profit increasing 25.4% to ₹75.4 crore. While annual revenue for FY26 saw a decline of 15.9% to ₹984.6 crore compared to FY25, the company maintained profitability with a full-year net profit of ₹207 crore. The Music segment remains the primary driver, contributing ₹200.4 crore in Q4, while the Artist Management segment showed explosive growth of 125% YoY. Despite the annual revenue dip, the company's margin management and recovery in the final quarter provide a positive outlook.
முக்கிய அம்சங்கள்
Q4 FY26 Consolidated Revenue grew 19.4% YoY to ₹287.4 crore compared to ₹240.8 crore in Q4 FY25.Q4 Net Profit (attributable to owners) increased 25.4% YoY to ₹75.4 crore from ₹60.1 crore.Artist Management segment revenue surged 125% YoY to ₹42.5 crore in the final quarter.Full-year FY26 revenue stood at ₹984.6 crore, a 15.9% decline from FY25's ₹1,171.4 crore, primarily due to lower Events and Video revenue.The company made a significant investment of ₹325.2 crore in an associate during the year, impacting cash balances.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong Q4 recovery and the rapid scaling of the high-margin Artist Management business. While annual revenue dipped, the core Music licensing business remains robust, and the company's ability to maintain profit levels suggests efficient cost management.
Saregama Q4 FY26: Highest Ever Quarterly EBITDA of Rs. 1,327 Mn, Up 31% YoY
Saregama reported a robust Q4 FY26 with revenue growing 19% YoY to Rs. 2,874 Mn and its highest-ever quarterly EBITDA. The core Music segment remains the primary growth engine, with annual revenue increasing 17% to Rs. 8,144 Mn and net margins expanding to 55% in Q4. While Live Events revenue declined 78% due to a high base effect from a major tour in FY25, the company is aggressively investing in new music IP and AI-driven content creation. Management projects a 20-23% CAGR for music revenue over the next 3-5 years.
முக்கிய அம்சங்கள்
Achieved highest ever quarterly Adj. EBITDA of Rs. 1,327 Mn, a 31% YoY increase.Music segment annual net margin grew by 28% YoY to reach Rs. 3,768 Mn.Highest ever annual investment in content with Rs. 2,354 Mn in new music and Rs. 1,047 Mn in catalogue purchases.Digital footprint reached 650 Mn+ followers across YouTube, Instagram, and Facebook.Live Events revenue fell to Rs. 618 Mn from Rs. 2,852 Mn in FY25 due to the absence of the Diljit Dosanjh India tour.
👀 கவனிக்க வேண்டியவை
Investors should view the strong margin expansion in the core music licensing business as a positive indicator of long-term profitability. The company's aggressive IP acquisition strategy and pivot toward AI-driven efficiency provide a solid moat against competitors.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Thyrocare reported a robust 21% YoY consolidated revenue growth for FY26, supported by a 23% increase in test volumes to 210 million. The specialized 'Jaanch' segment showed exceptional growth of 66% in Q4, while the flagship 'Aarogyam' brand grew 20%. Despite a slight dip in the partnership segment's Q4 growth to 23% due to a high base effect of INR 4 crore from the previous year, the company expanded its network to 10,800 franchisees and 41 labs globally. Strategic forays into genomics and the African market (Tanzania) signal a shift towards high-margin specialty diagnostics and geographic diversification.
முக்கிய அம்சங்கள்
Consolidated revenue grew 21% YoY in FY26, with Q4 revenue increasing by 20% YoY.Processed 210 million tests in FY26 (up 23% YoY) and served 19.2 million patients (up 15% YoY).The specialized 'Jaanch' portfolio surged 66% YoY in Q4, reflecting a shift toward disease-specific testing.Active franchisee network reached a record 10,800, while the lab network expanded to 41 locations including Tanzania.Maintained Six Sigma quality levels with complaints reduced to 3.06 per million tests and a turnaround time of 3.43 hours.
👀 கவனிக்க வேண்டியவை
Investors should monitor the scaling of the high-margin genomics and specialty segments, which are expected to drive future profitability. The company's expansion into Africa and its dominant B2B partnership growth make it a strong contender in the organized diagnostic space.
CARE Ratings Reports Strong FY26 Performance with 24% PAT Growth and Rs. 14 Final Dividend
CARE Ratings delivered a robust performance for FY26, with consolidated revenue growing 18% YoY to Rs. 473.07 crore and PAT increasing 24% YoY to Rs. 173.69 crore. The company maintained strong profitability, with consolidated EBITDA margins expanding to 42% for the full year. A final dividend of Rs. 14 per share has been recommended, bringing the total dividend for FY26 to Rs. 22 per share. Growth was well-distributed, with the core ratings segment growing 17% and the non-ratings segment increasing by 19%.
முக்கிய அம்சங்கள்
Consolidated PAT for FY26 rose 24% YoY to Rs. 173.69 crore, marking an all-time high.Consolidated Revenue from Operations increased 18% YoY to Rs. 473.07 crore in FY26.Recommended a final dividend of Rs. 14 per share, resulting in a total annual dividend of Rs. 22.Consolidated EBITDA grew by 27% YoY to Rs. 197.39 crore with a margin of 42%.Non-ratings segment revenue grew by 19% YoY to Rs. 50.01 crore, contributing 11% to total revenue.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the company's successful diversification into non-rating segments. The high dividend yield and strong cash flow generation make it an attractive pick for long-term portfolios.
CARE Ratings Recommends ₹14 Final Dividend and Re-appoints Statutory Auditors
CARE Ratings has recommended a final dividend of ₹14 per equity share for the financial year 2026, with the record date set for June 26, 2026. The company also approved the re-appointment of B S R & Co. LLP as statutory auditors for a five-year term until 2031. Additionally, 55,000 stock options were granted to employees at an exercise price of ₹1,590 per share. The company reported a delay in the partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC due to ongoing legal documentation.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.Re-appointed B S R & Co. LLP as Statutory Auditors for a 5-year term (2026-2031).Granted 55,000 ESOPs under the 2020 scheme at an exercise price of ₹1,590.Partial stake sale of CareEdge Global IFSC to SBI and NSE IFSC is still under negotiation due to documentation delays.
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold shares by the June 26 record date to qualify for the ₹14 dividend. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE IFSC as a potential catalyst for the stock.
CARE Ratings Declares ₹14 Dividend and Grants 55,000 ESOPs at ₹1,590 Exercise Price
CARE Ratings has recommended a final dividend of ₹14 per share for FY26, with the record date set for June 26, 2026. The company also approved the grant of 55,000 stock options to employees at an exercise price of ₹1,590 per share, vesting over three years. Additionally, the board provided an update on the delayed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC, confirming that negotiations are still active. B S R & Co. LLP has been re-appointed as the statutory auditor for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.Granted 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.Set June 26, 2026, as the record date for dividend eligibility.Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term until 2031.Confirmed ongoing negotiations for the stake sale in CareEdge Global IFSC Limited to SBI and NSE IFSC.
👀 கவனிக்க வேண்டியவை
Investors should note the ₹14 dividend and the June 26 record date for eligibility. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE as a potential valuation catalyst.
Religare FY26 Revenue Hits ₹8,494 Cr; Care Health GWP Grows 24% to ₹11,417 Cr
Religare Enterprises Limited (REL) reported a consolidated revenue of ₹8,494 crore for FY26, primarily driven by its health insurance subsidiary, Care Health, which saw a 24% YoY growth in Gross Written Premium (GWP) to ₹11,417 crore. The NBFC arm, Religare Finvest (RFL), turned profitable with a PAT of ₹138.8 crore for the full year, significantly improving its CRAR to 261.9% and reducing NNPA to 0.8%. The company is also progressing with a strategic demerger to separate its insurance and financial services businesses and has announced a ₹1,500 crore capital raise via convertible warrants.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue reached ₹8,494 Cr, led by Care Health Insurance's GWP of ₹11,417 Cr.Religare Finvest (RFL) reported a PAT of ₹138.8 Cr in FY26 compared to ₹24 Cr in FY25, with NNPA at a low 0.8%.Care Health Insurance maintained a 22% market share in the SAHI segment with a claim settlement ratio exceeding 97%.The Burman Group was designated as Promoters in Feb 2025, currently holding a ~30.3% stake.Board approved a demerger of the Financial Services business to Religare Finvest Limited for sharper segment focus.
👀 கவனிக்க வேண்டியவை
Investors should view the turnaround in the NBFC business and the sustained growth in the health insurance segment as positive indicators. Monitor the upcoming demerger process and the utilization of the ₹1,500 crore capital raise for future expansion.
Religare Enterprises Reports FY26 Standalone Net Loss of ₹33.80 Crore; Revenue Drops 60.7%
Religare Enterprises Limited reported a standalone net loss of ₹33.80 crore for the fiscal year ended March 31, 2026, a slight improvement from the ₹37.54 crore loss in the previous year. However, total income witnessed a significant decline of 60.7%, falling to ₹16.44 crore from ₹41.82 crore in FY25. While the company managed to reduce total expenses by 39.3% to ₹50.36 crore, it remains in a loss-making position. Investors should also note the auditor's emphasis on ongoing income tax litigations and related tax demands.
முக்கிய அம்சங்கள்
Annual standalone total income fell sharply to ₹16.44 crore in FY26 from ₹41.82 crore in FY25.Net loss for the full year narrowed slightly to ₹33.80 crore compared to ₹37.54 crore in the previous fiscal.Q4 FY26 standalone net loss stood at ₹12.36 crore versus a loss of ₹17.74 crore in Q4 FY25.Total annual expenses were reduced to ₹50.36 crore from ₹82.94 crore in the prior year.Statutory auditors issued an unmodified opinion but included an 'Emphasis of Matter' regarding ongoing income tax litigations.
👀 கவனிக்க வேண்டியவை
The company's standalone performance remains weak with a significant drop in revenue and persistent losses. Investors should exercise caution and closely monitor the resolution of tax litigations and the performance of its key subsidiaries in the consolidated report.
R. S. Software (India) Limited has officially approved its audited standalone and consolidated financial results for the quarter and full financial year ending March 31, 2026. The company confirmed that the statutory auditors have issued an unmodified opinion, suggesting no significant accounting discrepancies or qualifications. Furthermore, the company clarified that it does not qualify as a 'Large Corporate' under SEBI's debt issuance framework, meaning it is not mandated to raise incremental borrowings through debt securities. This announcement serves as a procedural confirmation of the company's financial reporting integrity for the fiscal year.
முக்கிய அம்சங்கள்
Board approved audited standalone and consolidated results for the financial year ending March 31, 2026.Statutory auditors issued an Unmodified Opinion on the financial results for the period.Company confirmed it does not meet the SEBI criteria for 'Large Corporate' status as of April 02, 2026.The Board meeting for result approval concluded at 1:50 PM on May 07, 2026.Q4 results were derived by subtracting nine-month figures from the full-year audited totals as per SEBI regulations.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial tables once available to evaluate specific revenue and margin trends, though the clean audit report is a positive sign of transparency. The non-applicability of the Large Corporate framework indicates the company's debt levels or market capitalization remain below the SEBI-defined thresholds.
Bajaj Healthcare FY26 Revenue Up 12.6% to ₹611 Cr; Net Profit Drops 60% on Exceptional Loss
Bajaj Healthcare reported a 12.6% YoY growth in annual revenue to ₹61,103 Lakhs for FY26. However, the company faced a significant net loss of ₹2,285 Lakhs in Q4 FY26, primarily due to a one-time exceptional item of ₹3,324 Lakhs related to a technical know-how income reversal from a Middle East contract. Annual net profit consequently declined by 60% to ₹1,576 Lakhs. Despite the profit hit, the board recommended a final dividend of ₹1.50 per share and successfully utilized ₹15,000 Lakhs from warrant conversions for debt repayment.
முக்கிய அம்சங்கள்
Annual Revenue from continuing operations grew 12.6% YoY to ₹61,103.14 Lakhs.Q4 FY26 reported a net loss of ₹2,285.06 Lakhs vs a profit of ₹1,117.78 Lakhs in the previous year's quarter.Exceptional loss of ₹3,324.66 Lakhs recognized in Q4 due to reversal of income from a technical know-how arrangement.Board recommended a final dividend of 30% (₹1.50 per equity share) for FY 2025-26.Company utilized ₹15,000 Lakhs from preferential issue proceeds for loan repayment, significantly reducing debt.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to stabilize margins following the one-time income reversal and the progress of the Genrx Pharmaceuticals acquisition. While the debt reduction is a positive structural change, the volatility in contract-based income suggests a need for caution.
Bajaj Healthcare FY26 PAT Rises 27% to ₹545.6 Mn; API Exports Surge 51.6%
Bajaj Healthcare reported a 12.6% YoY revenue growth for FY26, reaching ₹6,110.3 Mn, driven primarily by a robust 51.6% surge in API exports. While Q4 revenue was flat due to domestic API price erosion, PAT from continuing operations grew 19.3% in Q4 and 27.1% for the full year. The company strengthened its balance sheet by raising ₹527 Mn through warrant conversion and expanded its pipeline with 41 new DMF filings in Q4. However, a one-time reversal of income from a Middle East contract due to regional instability impacted the final reported profit.
முக்கிய அம்சங்கள்
FY26 Revenue grew 12.6% to ₹6,110.3 Mn, with API exports jumping 51.6% to ₹1,881.4 Mn.PAT from continuing operations (before exceptional items) increased 27.1% YoY to ₹545.6 Mn in FY26.Company filed 41 DMFs in Q4 FY26, bringing the cumulative total to 110 to target regulated markets.Raised ₹527 Mn through the conversion of 2,079,409 warrants into equity shares to support growth.Cenobamate (anti-epileptic) is on track for a Q2 FY27 launch following Phase III trials.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful launch of Cenobamate in Q2 FY27 and the scaling of the CDMO segment as key growth drivers. The strong export momentum and regulatory filings suggest a positive shift towards higher-margin regulated markets.
Bajaj Healthcare reported a 12.6% YoY increase in FY26 revenue to Rs. 611.03 crore, though net profit fell significantly to Rs. 15.77 crore from Rs. 39.50 crore in FY25. The Q4 performance was severely impacted by a one-time exceptional loss of Rs. 33.25 crore due to the reversal of technical know-how income linked to Middle East instability. Despite a Q4 net loss of Rs. 22.85 crore, the board recommended a final dividend of Rs. 1.50 per share. The company also strengthened its capital base by raising Rs. 52.71 crore through warrant conversions.
முக்கிய அம்சங்கள்
FY26 Revenue from operations increased to Rs. 61,103.14 lakhs from Rs. 54,260.24 lakhs in FY25.Reported a significant exceptional item of Rs. 3,324.66 lakhs in Q4 FY26 due to income reversal.Total Net Profit for FY26 dropped to Rs. 1,576.61 lakhs compared to Rs. 3,949.55 lakhs in the previous year.Recommended a final dividend of Rs. 1.50 per equity share (30% of face value of Rs. 5).Raised Rs. 5,271.30 lakhs through the conversion of 20,79,409 warrants into equity shares for debt repayment and CAPEX.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the sharp decline in profitability and the large income reversal indicate high sensitivity to geopolitical risks. Monitor the successful integration of the Genrx acquisition and the impact of debt repayment on future margins.
Religare Subsidiary RHDFCL Appoints Pankaj Rathi as Executive Director and CFO
Religare Enterprises' step-down subsidiary, Religare Housing Development Finance Corporation Limited (RHDFCL), has appointed Mr. Pankaj Rathi as Executive Director and CFO effective April 06, 2026. Mr. Rathi brings over 15 years of experience in the BFSI sector, specifically in financial reporting, fundraising, and M&A. He previously served as CFO at Grihum Housing Finance, where he successfully raised over $1.3 billion in capital. This appointment is expected to strengthen the strategic and financial leadership of Religare's housing finance business.
முக்கிய அம்சங்கள்
Mr. Pankaj Rathi appointed as Additional Director and Whole-Time Director (ED & CFO) of RHDFCL.Appointee has over 15 years of experience and previously raised $1.3 billion in capital over 5 years.Track record includes orchestrating a credit rating migration from AA- to AAA in a previous role.Appointment is subject to the approval of shareholders of the subsidiary company.
👀 கவனிக்க வேண்டியவை
Investors should monitor if this leadership change leads to improved credit ratings and lower borrowing costs for the housing finance subsidiary. The appointee's strong track record in fundraising and M&A is a positive sign for the company's growth trajectory.
Religare Finvest Appoints Srinivasan Karthik as CEO and Managing Director
Religare Enterprises Limited's material subsidiary, Religare Finvest Limited (RFL), has appointed Mr. Srinivasan Karthik as its Chief Executive Officer and Key Managerial Personnel effective May 05, 2026. Mr. Karthik brings over 30 years of extensive experience, including a 10-year tenure at HDB Financial Services where he scaled consumer and asset finance portfolios. His further designation as Managing Director is currently pending approval from the Reserve Bank of India (RBI) and shareholders. This appointment is a strategic move to strengthen the leadership at RFL, leveraging his expertise in digital transformation and financial services.
முக்கிய அம்சங்கள்
Mr. Srinivasan Karthik appointed as CEO of Religare Finvest Limited effective May 05, 2026Brings 30+ years of experience in financial services, consumer financing, and asset financingPreviously spent a decade at HDB Financial Services building large-scale loan portfoliosEducational credentials include a B.Tech from IIT Delhi and a PGDM from IIM BangaloreDesignation as Managing Director is subject to upcoming RBI and shareholder approvals
👀 கவனிக்க வேண்டியவை
Investors should monitor the regulatory approval process for the Managing Director role as it signals stability in the subsidiary's leadership. The appointment of a high-pedigree professional from a major NBFC like HDB Financial is a positive indicator for RFL's future growth and digital strategy.
Waaree Energies FY26 PAT Doubles to ₹3,884 Cr; Order Book Reaches ₹53,000 Cr
Waaree Energies delivered a record-breaking FY26 performance with revenue growing 84% YoY to INR 26,537 crores and PAT doubling to INR 3,884 crores. The company surpassed its EBITDA guidance, achieving INR 6,617 crores, supported by a robust module production of 12.6 GW. With a massive order book of INR 53,000 crores and a planned capex of INR 30,000 crores, the company is aggressively pursuing vertical integration into glass, ingots, and wafers. The retail segment also showed strong momentum, contributing INR 5,515 crores to the total revenue.
முக்கிய அம்சங்கள்
Revenue from operations grew 84% YoY to INR 26,537 crores with an operating EBITDA margin of 22.27%Order book stands robust at approximately INR 53,000 crores, providing strong multi-year revenue visibilityTotal module manufacturing capacity reached 26 GW, making it the largest non-Chinese manufacturer globallyStrategic acquisition of 55% stake in Associated Power Structures for INR 1,225 crores to enter the T&D segmentPlanned capex of INR 30,000 crores for backward integration including a 10 GW ingot wafer facility in Nagpur
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition toward a fully integrated energy player and its ability to surpass financial guidance. The aggressive backward integration and expansion into the US market are key long-term growth drivers to monitor.
Thyrocare Declares ₹7 Final Dividend and ₹5.5 Cr Investment in Subsidiary
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total dividend for FY26 to ₹9.33 per share post-bonus adjustment. The company is investing up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics, to bolster its diagnostic capabilities. Leadership remains stable with the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term. Furthermore, the company is broadening its business scope via MOA amendments to include digital healthcare platforms and allied services.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹7.00 per equity share for FY 2025-26.Total FY26 dividend stands at ₹9.33 per share post-bonus adjustment.Approved equity infusion of up to ₹5.50 crore in Think Health Diagnostics Private Limited.Re-appointed Rahul Franklin Guha as MD & CEO for a 5-year term starting May 2027.Proposed MOA alteration to expand business into digital platforms and broader healthcare services.
👀 கவனிக்க வேண்டியவை
Investors should take note of the consistent dividend payout and leadership continuity as positive indicators of corporate health. The strategic expansion into digital diagnostic platforms and allied services suggests a long-term growth roadmap beyond traditional pathology.
Thyrocare Recommends Rs 7 Dividend, Re-appoints CEO, and Invests Rs 5.5 Cr in Subsidiary
Thyrocare's board has recommended a final dividend of Rs 7.00 per share, bringing the total FY26 dividend to Rs 9.33 per share post-bonus adjustment. The company is re-appointing Rahul Franklin Guha as CMD & CEO for another five-year term and has approved a fresh investment of up to Rs 5.50 crore in its subsidiary, Think Health Diagnostics. Additionally, the company is broadening its Memorandum of Association to include a wider range of healthcare and digital diagnostic services. Significant board reshuffling also occurred with two resignations and two new appointments of non-executive directors.
முக்கிய அம்சங்கள்
Recommended final dividend of Rs 7.00 per share; total FY26 dividend stands at Rs 9.33 post-bonus adjustmentRe-appointment of Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027Approved investment of up to Rs 5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private LimitedAppointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year termProposed MOA changes to broaden business scope into digital platforms and allied healthcare services
👀 கவனிக்க வேண்டியவை
Investors should find the dividend payout and leadership continuity as positive indicators of stability. The strategic expansion of the business scope via MOA amendments suggests a long-term growth plan in the digital healthcare ecosystem.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
